Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The 24 – 30 April is World Immunisation Week with the focus of this year’s WHO campaign is “Close the immunisation gap”.  NDM and Paediatrics spoke to Professor Calman MacLennan, Professor of Vaccine Immunology (University of Birmingham) and Jenner Investigator and Dr Manish Sadarangani Clinical Lecturer and Honorary Consultant in Paediatric Infectious Diseases and Immunology at The Children’s Hospital, Oxford about vaccinations and how we can “close the gap” and get more people vaccinated to prevent deadly diseases.  

 

To mark World Immunisation Week, Dr Manish Sadarangani Clinical Lecturer and Honorary Consultant in Paediatric Infectious Diseases and Immunology at The Children’s Hospital, Oxford explains how herd immunity works and why vaccinating children is important.

Q: What is herd immunity?

Manish SadaranganiManish Sadarangani: Herd immunity describes how a population is protected from a disease after vaccination by stopping the germ responsible for the infection being transmitted between people. In this way even people who cannot be vaccinated can be protected. For example, the bacteria meningococcus and pneumococcus can cause blood poisoning (septicaemia) and meningitis.  In most people the bacteria live harmlessly in the throat and do not causes disease, but sometimes they get into the bloodstream leading to these severe infections. They can live harmlessly in the throat of one person but if they spread to someone who is particularly susceptible (such as a young baby) they can cause severe disease. By being vaccinated an individual is not only protected from being infected themselves but they then also cannot pass this infection onto other people, where it may cause severe disease. However, for herd immunity to work a large proportion of the population need to be vaccinated.  

Herd immunity People are shown as circles. Infectious agents (germs) spread between the people in orange, although they do not get severe disease. When the infection reaches people who are highly susceptible (red) they get the disease and can be very sick or die.

In the lower panel, the people in green have been vaccinated. This now protects those in yellow as well, who had previously got the infection and possibly the disease. Although the figure only shows a few people being vaccinated, in reality many people have to be vaccinated for herd immunity to work.

Q: Why is it important that children are vaccinated if they can be protected through herd immunity?

MS: For many diseases children, and in particular young children, are at the highest risk of the disease and also have the most severe illness. The best way to protect someone against a disease is to vaccinate them directly, rather than rely on ‘indirect’ protection through herd immunity. If someone who is unvaccinated does meet the germ responsible for that disease they will be completely susceptible. There will always be some children who cannot be vaccinated for medical reasons – most commonly because they are too young or because they have a problem with their immune system. It doesn’t take much of a drop in the number of people vaccinated in a population for herd immunity to be less effective and this isn’t then a reliable way of protecting a child.

Q: How many children need to be vaccinated for herd immunity to work?

MS: This varies depending on the germ and how contagious it is. The more contagious it is then the more people need to be vaccinated for herd immunity to work. For example, measles is very contagious. Before the use of the measles vaccine, every person with measles would infect another 10-15 people and so the disease would spread very quickly. To achieve herd immunity for measles at least 90-95% of the population need to be vaccinated. A disease like polio is less contagious, and 80-85% of the population would need to be vaccinated for herd immunity to work. Although this is lower it is still a very high proportion, especially given that some people cannot be vaccinated for medical reasons.

Q: Does herd immunity work for all diseases?

MS: No. Herd immunity only works for diseases that are spread directly between people (i.e. are ‘contagious’), like measles. One example where it would not work is tetanus. The bacteria which cause tetanus lives in the soil, so anyone who is not vaccinated would be susceptible and could easily be infected if they were exposed to bacteria in the soil, such as through a dirty wound, even if everyone else around them was vaccinated and protected.

Q: The theme of this year’s Immunisation Week is ‘Closing the Immunisation Gap’. What do you think we can do to close this gap?

MS: We need to identify reasons why some populations in the world have lower immunisation rates than others and then try to come up with solutions to address them. Many children every day get sick and die from diseases which we already have vaccines for but in some populations many children are not receiving them. It is likely that different problems will be present in different areas and solutions need to be tailor-made to the problems in each case. We also need more research to know how much disease there is throughout the world, particularly in developing countries where it is more difficult to do this research. This will help prioritise vaccine development programmes and also identify which populations need the vaccine most. This is more easily said than done, and needs ongoing collaboration on an international scale with political will and financial backing. This needs to be made a global health priority given that vaccines are the most effective and cost-efficient healthcare intervention we have.

Related news

World immunisation week: Why should we vaccinate?

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.